Compare Salesforce Inc (CRM) vs Moderna, Inc. (MRNA) Price & Performance

Salesforce IncTrade

Moderna, Inc.Trade

Price performance (Past 24H)

Key statistics

Salesforce Inc vs Moderna, Inc. — how do they compare? Salesforce Inc trades at $167.4 (market cap $137.23B), while Moderna, Inc. trades at $68.42 (market cap $26.76B). The key difference: Salesforce Inc is far larger — about 5.1× Moderna, Inc.'s market cap, and Salesforce Inc pays a 1.05% dividend while Moderna, Inc. pays none. Which is the better fit depends on your goals.

	CRM	MRNA
Market Cap	$137.23B	$26.76B
Sector	Technology	Health
52-Week High	$270.25	$81.80
52-Week Low	$150.12	$22.36
Enterprise Value	$167.28B	$22.85B
Dividend Yield	1.05%	—

View details →View details →

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Salesforce Inc

Salesforce (CRM) trades at $167.56, down 2.14% amid broader tech sector weakness. The stock shows strong fundamentals with consistent earnings beats (Q1 2026 EPS of $3.88 vs. $3.13 expected) and robust profitability (77.64% gross margin). Technical indicators are neutral with support at $165 and resistance at $171. Recent news highlights AI momentum but also sector-wide software stock pressure.

Outlook remains positive with analyst consensus target of $235.90 (40% upside) and 76.84% buy ratings. Key opportunities include AI monetization growth (Agentforce ARR up 200% YoY), while risks include competitive AI landscape and macroeconomic headwinds affecting software spending.

Moderna, Inc.

Moderna (MRNA) trades at $67.01, down 1.85% today, with a bullish technical signal from moving averages. The company continues to post net losses despite beating EPS estimates in recent quarters, with revenue declining from pandemic peaks. Recent news highlights pipeline expansion into oncology and autoimmune diseases, with an FDA decision on its mRNA flu vaccine expected by August 5, 2026.

While Moderna's pipeline diversification offers long-term growth potential, significant risks remain from persistent negative profitability and high valuation multiples. Analyst consensus is cautious with a $49 price target below current levels, suggesting limited near-term upside despite recent positive developments in vaccine approvals and strategic shifts.

Aura AI is an analytical signal, not financial advice — do your own research.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

CRM

Social media analytics market to hit $107.3B by 2035 with 25.16% CAGR, driven by AI and rising social media useGlobe News Wire · 1 day agoBullish IBM warns of slowing growth as AI shifts corporate spending to infrastructure, shares plunge 25%.New York Post · 1 day agoBearish AI costs could hurt company earnings as hidden spending surprises CEOs, warns investor Chamath Palihapitiya.CNBC · 1 day agoBearish View details →

MRNA

Moderna's Q2 report expected uneventful; key focus on COVID vaccine demand and Phase III melanoma data.Proactive Investors · 1 day agoNeutral View details →

About Salesforce Inc

Salesforce Inc provides enterprise cloud computing solutions. The company offers customer relationship management technology that brings companies and customers together. Its Customer 360 platform helps the group to deliver a single source of truth, connecting customer data across systems, apps, and devices to help companies sell, service, market, and conduct commerce. It also offers Service Cloud for customer support, Marketing Cloud for digital marketing campaigns, Commerce Cloud as an e-commerce engine, the Salesforce Platform, which allows enterprises to build applications, and other solutions, such as MuleSoft for data integration.

About Moderna, Inc.

Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.